Reports
Sale
Global Allogeneic T Cell Therapies Market Size, Share, Growth, Analysis, Forecast: By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies, Others; By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Allogeneic T Cell Therapies Market Outlook
The global allogeneic T cell therapies market size is anticipated to grow at a CAGR of 9.75% during the forecast period of 2024-2032, driven by the rising prevalence of cancer cases across the globe.
Allogeneic T Cell Therapies: Introduction
Allogeneic or universal cell therapies rely on a single source of cells to treat patients. Cells are collected from a healthy person’s body and directly transferred into the patient’s body or developed into a master cell bank (MCB). There are several advantages of using allogenic treatments and one of them is easy availability of cells and tissues. However, allogeneic treatments may also be responsible for transmitting infections or diseases. The use of allogeneic cell therapy is majorly performed in patients whose own stems cells cannot be transplanted, such as people suffering from leukemia.
Global Allogeneic T Cell Therapies Market Analysis
The prevalence of chronic diseases like cancer has been increasing rapidly owing to the unhealthy lifestyles and carcinogenic environment, among other factors. The awareness about the importance of getting a timely treatment for cancer is also growing among the population. This has increased the need for advanced and efficient treatments and therapies, including allogeneic T cell therapies. With the rising number of patients opting for timely treatments owing to the advanced diagnostic tests and treatments available for cancer, the demand for allogeneic T cell therapies is likely to grow further in the coming years. Allogeneic T cell therapies have gained significant popularity among oncologists as they offer efficient benefits to the patient in fighting the cancer cells.
Governments of several countries are taking initiatives to improve their healthcare systems in order to provide the best treatment to the patients with an overall enhanced patient experience. The increasing number of research and development activities for allogeneic T-cell therapy significantly adds to the global allogeneic T cell therapy market growth. Recent research has exhibited the advancement of Chimeric antigen receptor (CAR) T cell therapy, which was previously used for treating blood cancers like leukemia, lymphoma, and multiple myeloma. It has now shown effective action against solid tumours from lung cancer to kidney cancer to bone cancer as well.
The increasing number of approvals is also influencing the market growth. For example, six CAR T cell therapies that demonstrated efficacy in patients with B-cell malignancies and multiple myeloma, which was never seen before, have been approved officially. Additionally, the increasing investment by pharmaceutical companies are also likely to add significantly to the global allogeneic T cell therapy market share.
The increasing collaborations among the key players are also aiding the growth of the market. For instance, a collaboration between HaemaLogiX and Peter MacCallum Cancer Centre took place in August 2024, which is expected to result in the advancement of KMA, Kappa Myeloma Antigen, which is a receptor solely appearing on myeloma cells in kappa-type MM.
Global Allogeneic T Cell Therapies Market Segmentations
Market Breakup by Product Type
- Chimeric Antigen Receptor (CAR) T Cell Therapies
- T Cell Receptor (TCR) Therapies
- Others
Market Breakup by Therapeutics Indications
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Allogeneic T Cell Therapies Market Overview
The growth of the global market for allogeneic T cell therapy is driven by the rising accessibility of gene therapies in the market. The growth is also driven by the rising geriatric and paediatric patient population, and the increasing prevalence of chronic diseases, such as cancer. The rising awareness about gene cell therapies and its benefits are further aiding the market demand. Due to the increasing awareness, the demand for effective gene and cell treatment therapies is also increasing, further propelling the global allogeneic T cell therapy market value. The expenditure against T cell therapies is also rising, which is likely to provide further impetus to the growth of the market.
Allogeneic T Cell Therapies Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Athersys Inc.
- Mesoblast Ltd.
- Biorestorative Therapies Inc.
- Pluristem Inc.
- Brainstorm Cell Limited.
- ViaCyte Inc.
- Gamida Cell
- HOPE BIOSCIENCES
- Cellular Biomedicine Group
- Smith+Nephew
- MEDIPOST
- ANTEROGEN.CO, LTD.
- NuVasive Inc.
- RTI Surgical
- AlloSource
- JCR Pharmaceuticals Co. Ltd.
- Takeda Pharmaceutical Company Limited
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Prodcut Type |
|
| Breakup by Therapeutics Indications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Allogeneic T Cell Therapies Market Overview
3.1 Global Allogeneic T Cell Therapies Market Historical Value (2017-2023)
3.2 Global Allogeneic T Cell Therapies Market Forecast Value (2024-2032)
4 Global Allogeneic T Cell Therapies Market Landscape
4.1 Global Allogeneic T Cell Therapies Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Allogeneic T Cell Therapies Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Indications
4.2.3 Analysis by End User
5 Global Allogeneic T Cell Therapies Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Allogeneic T Cell Therapies Market Segmentation
6.1 Global Allogeneic T Cell Therapies Market by Product Type
6.1.1 Market Overview
6.1.2 Chimeric Antigen Receptor (CAR) T Cell Therapies
6.1.3 T Cell Receptor (TCR) Therapies
6.1.4 Others
6.2 Global Allogeneic T Cell Therapies Market by Therapeutics Indications
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Autoimmune Diseases
6.2.4 Infectious Diseases
6.2.5 Others
6.3 Global Allogeneic T Cell Therapies Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Specialty Clinics
6.3.4 Research Institutes
6.3.5 Others
6.4 Global Allogeneic T Cell Therapies Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Allogeneic T Cell Therapies Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Allogeneic T Cell Therapies Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Allogeneic T Cell Therapies Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Allogeneic T Cell Therapies Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Allogeneic T Cell Therapies Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Athersys Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Mesoblast Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Biorestorative Therapies Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Pluristem Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Brainstorm Cell Limited.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 ViaCyte Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Gamida Cell
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 HOPE BIOSCIENCES
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Cellular Biomedicine Group
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Smith+Nephew
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 MEDIPOST
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 ANTEROGEN.CO, LTD.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 NuVasive Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 RTI Surgical
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 AlloSource
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
17.16 JCR Pharmaceuticals Co. Ltd.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisition
17.16.5 Certifications
17.17 Takeda Pharmaceutical Company Limited
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisition
17.17.5 Certifications
18 Global Allogeneic T Cell Therapies Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 9.75% during the forecast period of 2024-2032.
The rising awareness and demand for cell therapies in the market are among the major factors driving the market growth.
The increasing number of research and development activities and increasing collaborations between companies to develop more effective cell therapies are among major trends influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
The products available in the market include chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies, among others.
Different therapeutic indications include cancer, autoimmune diseases, and infectious diseases, among others.
The end users in the market include hospitals, specialty clinics, and research institutes, among others.
Key players involved in the market are Athersys Inc., Mesoblast Ltd., Biorestorative Therapies Inc., Pluristem Inc., Brainstorm Cell Limited., ViaCyte Inc., Gamida Cell, HOPE BIOSCIENCES, Cellular Biomedicine Group, Smith+Nephew, MEDIPOST, ANTEROGEN.CO, LTD., NuVasive Inc., RTI Surgical, AlloSource, JCR Pharmaceuticals Co. Ltd., and Takeda Pharmaceutical Company Limited.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER